but use of any ART combination approved by the FDA for initial treatment of HIV infection was allowed. All patients in the early group and 91% of those in the delayed group actually initiated ART ...
Among treatment-naive people with HIV, dolutegravir/lamivudine showed viral suppression comparable with those of other first-line antiretroviral therapies, with lower discontinuation rates.